XML 101 R74.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Note 15 - Forward Contract (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended 31 Months Ended
Jun. 13, 2022
Nov. 12, 2020
Jun. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Nov. 12, 2022
Dec. 31, 2020
Unrealized Gain (Loss) on Derivatives       $ (0) $ 1,071,000 $ 444,000    
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]                
Derivative Liability, Total $ 1,237,000             $ 278,000
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Forward Liability [Member]                
Derivative Liability, Total   $ 278,000            
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Forward Contract [Member]                
Derivative Asset, Total 1,237,000       0 166,000    
Unrealized Gain (Loss) on Derivatives           $ 444,000    
Gain (Loss) on Sale of Derivatives         $ 1,071,000      
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Additional Series A-2 Preferred Shares [Member]                
Stock Issued During Period, Value, New Issues             $ 1,990,000  
Shares Issued, Price Per Share (in dollars per share)             $ 2.5125  
Stock Issued During Period, Shares, New Issues (in shares)             1,990,000  
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-2 Preferred Shares [Member]                
Stock Issued During Period, Value, New Issues $ 5,000,000   $ 5,000,000          
Shares Issued, Price Per Share (in dollars per share)   $ 2.5125            
Stock Issued During Period, Shares, New Issues (in shares) 1,990,000 1,990,000 1,990,000